Magictouch AVF in salvage of AVG Clinical Trial | Concept Medical
MAGICTOUCH AVF IN SALVAGE OF AVG

CONCLUSION

• Treatment with Sirolimus coated balloon at the graft vein junction after successful salvage of thrombosed arteriovenous graft appears to be useful.
• Alternative to Paclitaxel coated balloon in dialysis access interventions.

  • Principal Investigator
    Dr. Tan Chieh Suai
    Department of Renal Medicine, Singapore General Hospital, Singapore
STUDY DETAILS: OBJECTIVE

STUDY DESIGN

• This is a phase 2, pilot clinical trial to investigate the effect of SCB on thrombosed AVG.

Study Endpoints:

Primary Endpoints:
• 3-Months unassisted patency as patency of the AVG without the need for any angioplasty or repeat thrombolysis within 3 months after successful thrombolysis.

Secondary Endpoints:
• Clinical and angiographic re-stenosis of the AVG and the number of interventions needed to maintain the patency (assisted patency) of the circuit at 6-months.

ENROLMENT OF PATIENTS
ENROLMENT OF PATIENTS - MAGICTOUCH AVF IN SALVAGE OF AVG
BASELINE CHARACTERISTICS
BASELINE CHARACTERISTICS - MAGICTOUCH AVF IN SALVAGE OF AVG
OUTCOME OF INTERVENTIONS
OUTCOME OF INTERVENTIONS - MAGICTOUCH AVF IN SALVAGE OF AVG
OUTCOME OF INTERVENTIONS
OUTCOME OF INTERVENTIONS - MAGICTOUCH AVF IN SALVAGE OF AVG
PRIMARY PATENCY
PRIMARY PATENCY - MAGICTOUCH AVF IN SALVAGE OF AVG